November 19, 2018

New Peanut Allergy Drug Shows ‘Lifesaving’ Potential

The American College of Allergy, Asthma & Immunology announced results of a yearlong clinical trial of an oral immunotherapy regimen that may lead to approval of what could be the first oral medication that ameliorates reactions in children with severe peanut allergies.

Dr. James R. Baker, Jr., Director of the Mary H. Weiser Food Allergy Center was interviewed for the NY Times article discussing the yearlong clinical trial of an oral immunotherapy regimen that aims to reduce children’s sensitivity to peanut allergens by gradually exposing them to peanut protein over the course of six months, starting with minute amounts that are carefully measured and increased incrementally under medical supervision as tolerance develops.

Read full article HERE: